[Articular and muscular hemorrhages in hemophilia A with anti-factor VIII antibodies. Treatment with selected batches of PPSB (factor IX concentrate)].
Over a 10-month period, 65 bleeding episodes in 14 hemophilia A patients with anti-Factor VIII antibodies were treated with a non-activated Factor IX concentrate (PPSB). A single dose of 58-102 U/kg of Factor IX (average 80 U/kg) was used in 51 hemarthroses, 13 muscle hematomas and one dental bleed. Overall clinical results were satisfactory in 51% of cases. Forty nine per cent of acute hemarthroses were clinically improved. Safety tests were unchanged and no significant elevation of anti-VIII: C titers was recorded. These preliminary results ae similar to those obtained with single doses of activated prothrombin complex concentrates given to the same patients (Autoplex and FEIBA).
Verroust
F
F
Moussard
C
C
Allain
J P
JP
D000293:Adolescent; D000328:Adult; D001323:Autoantibodies / Q000032:analysis; D001779:Blood Coagulation Factors / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005164:Factor IX / Q000627:therapeutic use; D015949:Factor IXa; D005169:Factor VIII / Q000276:immunology; D006467:Hemophilia A / Q000150:complications / Q000276:immunology / Q000628:therapy*; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D007592:Joint Diseases / Q000209:etiology; D008297:Male; D009135:Muscular Diseases / Q000209:etiology
D001323:Autoantibodies; D001779:Blood Coagulation Factors; C025667:prothrombin complex concentrates; D005169:Factor VIII; D005164:Factor IX; D015949:Factor IXa
Hémorragies articulaires et musculaires des hémophiles A avec anticorps anti-facteur VIII. Traitement par des lots sélectionnés de PPSB (concentré de facteur IX).